In this issue:
- Perceived barriers to self-collected HPV testing
- Improving follow-up of abnormal cervical cancer screening results
- Neratinib for HER2-mutant metastatic cervical cancer
- Mucinous ovarian carcinoma: A survey of practice in Australia and NZ
- Reproductive outcomes after malignant ovarian germ cell tumour treatment
- Checkpoint inhibition in hypercalcemic ovarian small-cell carcinoma
- Survival consequences of baseline symptom burden in recurrent ovarian cancer
- Concordance of cancer antigen-125 and RECIST assessment of progression
- Mirvetuximab soravtansine in ovarian cancer
- Impact of obesity on identification of sentinel lymph node
Please login below to download this issue (PDF)